MX2011013453A - Agentes antimicrobianos. - Google Patents
Agentes antimicrobianos.Info
- Publication number
- MX2011013453A MX2011013453A MX2011013453A MX2011013453A MX2011013453A MX 2011013453 A MX2011013453 A MX 2011013453A MX 2011013453 A MX2011013453 A MX 2011013453A MX 2011013453 A MX2011013453 A MX 2011013453A MX 2011013453 A MX2011013453 A MX 2011013453A
- Authority
- MX
- Mexico
- Prior art keywords
- relates
- present
- gram
- nucleic acid
- acid molecules
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4723—Cationic antimicrobial peptides, e.g. defensins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
- C12N9/2462—Lysozyme (3.2.1.17)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/035—Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Pharmacology & Pharmacy (AREA)
- Communicable Diseases (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Enzymes And Modification Thereof (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Food Preservation Except Freezing, Refrigeration, And Drying (AREA)
- Cosmetics (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
La presente invención se refiere a agentes antimicrobianos contra bacterias Gram-positivas, en particular a proteínas de fusión compuestas de una enzima que tiene la actividad de degradar la pared celular de bacterias Gram-positivas y a un tramo de péptido adicional fusionado a la enzima en el extremo N o C. Además, la presente invención se refiere a moléculas de ácido nucleico que codifican para la proteína de fusión, a vectores que comprenden las moléculas de ácido nucleico y a células hospederas que comprenden ya sea las moléculas de ácido nucleico o los vectores. Además, la presente invención se refiere a la proteína de fusión para usarse como un medicamento, en particular para el tratamiento o prevención de infecciones por bacterias Gram-positivas, como medio de diagnóstico o como sustancia cosmética. La presente invención se refiere también al tratamiento o prevención de la contaminación por bacterias Gram-positivas de productos alimenticios, de equipo de procesamiento de alimentos, de plantas procesadoras de alimentos, de superficies que entran en contacto con alimentos, de dispositivos médicos, de superficies en hospitales y quirófanos. Además, la presente invención se refiere a una composición farmacéutica que comprende la proteína de fusión.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP09163955 | 2009-06-26 | ||
PCT/EP2010/059152 WO2010149795A1 (en) | 2009-06-26 | 2010-06-28 | Antimicrobial agents |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2011013453A true MX2011013453A (es) | 2012-04-11 |
Family
ID=42537604
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2011013453A MX2011013453A (es) | 2009-06-26 | 2010-06-28 | Agentes antimicrobianos. |
Country Status (13)
Country | Link |
---|---|
US (2) | US20120195872A1 (es) |
EP (2) | EP3363896A1 (es) |
JP (2) | JP6034188B2 (es) |
KR (1) | KR101701890B1 (es) |
CN (1) | CN102482655B (es) |
AU (1) | AU2010264659B2 (es) |
BR (1) | BRPI1015203B1 (es) |
CA (1) | CA2765810C (es) |
EA (1) | EA038542B1 (es) |
IL (1) | IL217121B (es) |
MX (1) | MX2011013453A (es) |
SG (1) | SG177704A1 (es) |
WO (1) | WO2010149795A1 (es) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20170024129A (ko) | 2009-06-26 | 2017-03-06 | 카톨리에케 유니버시테이트 루벤 | 항균제 |
KR101701890B1 (ko) | 2009-06-26 | 2017-02-02 | 뤼산도 아게 | 항균제 |
MX2012002216A (es) | 2009-08-24 | 2012-04-10 | Univ Leuven Kath | Nueva endolisina obpgplys. |
JP6058540B2 (ja) * | 2010-09-17 | 2017-01-11 | テクニファー−インダストリア テクニカ ファーマシューティカ,エス.エー. | 抗菌性ファージ、ファージペプチド、及びそれらの使用方法 |
EP2468856A1 (en) * | 2010-12-23 | 2012-06-27 | Lysando Aktiengesellschaft | Antimicrobial Agents |
CN102766196B (zh) * | 2011-05-06 | 2014-10-29 | 上海医药工业研究院 | 一组阳离子抗菌肽及其制备方法和应用 |
CN103361341B (zh) * | 2012-03-26 | 2015-09-02 | 复旦大学附属华山医院 | 杀菌肽ll-37的基因工程的表达及其制备方法和用途 |
EP2679232A1 (en) * | 2012-06-29 | 2014-01-01 | Lysando Aktiengesellschaft | Composition for use in Mycobacteria vaccination |
EP2679677A1 (en) * | 2012-06-29 | 2014-01-01 | Lysando Aktiengesellschaft | Composition for use in Mycobacteria therapy |
US9388400B2 (en) | 2012-06-29 | 2016-07-12 | Lysando Ag | Composition for use in mycobacteria diagnosis |
CN105579053B (zh) * | 2013-08-06 | 2021-08-31 | 达特茅斯学院理事会 | 非糖基化溶葡球菌素变体蛋白 |
WO2015070911A1 (en) | 2013-11-14 | 2015-05-21 | Lysando Ag | Modified kz144 endolysin sequence |
WO2015070912A1 (en) | 2013-11-14 | 2015-05-21 | Lysando Ag | Modified el188 endolysin sequence |
EP2904912A1 (en) * | 2014-02-07 | 2015-08-12 | Hyglos Invest GmbH | Novel high pressure method with endolysin for processing of foods |
US10329550B2 (en) | 2014-02-14 | 2019-06-25 | Lysando Ag | Antimicrobial agents |
WO2016029920A1 (en) * | 2014-08-29 | 2016-03-03 | Aarhus Universitet | Positively charged co-polymers for use as antimicrobial agents |
WO2016130024A1 (en) * | 2015-02-13 | 2016-08-18 | Supreme Biotechnologies Limited | Endolysin expression platform |
CA3022334A1 (en) * | 2016-04-28 | 2017-11-02 | Lysando Ag | Antimicrobial agents against salmonella bacteria |
BR112019007979A2 (pt) * | 2016-10-20 | 2019-07-09 | Lysando Ag | novos agentes antimicrobianos contra bactérias enterococcus |
WO2018185634A1 (en) * | 2017-04-03 | 2018-10-11 | Sasinapas Co., Ltd. | Engineered gram-negative endolysins |
CN108018271B (zh) * | 2018-01-31 | 2020-08-11 | 武汉核圣生物技术有限公司 | 单亚基rna聚合酶、其纯化方法及在rna合成中的应用 |
CN112368376A (zh) * | 2018-03-29 | 2021-02-12 | 康特拉费克特公司 | 溶素-抗微生物肽(amp)多肽构建体、溶素、其分离的编码多核苷酸及其用途 |
AU2019276253A1 (en) * | 2018-05-30 | 2020-11-26 | Lysando Ag | Novel antimicrobial proteins |
KR20210049023A (ko) * | 2018-08-23 | 2021-05-04 | 콘트라펙트 코포레이션 | 리신-항미생물 펩타이드(amp) 폴리펩타이드 작제물, 리신, 이를 인코딩하는 단리된 폴리뉴클레오타이드 및 이의 용도 |
US20230106068A1 (en) * | 2020-03-02 | 2023-04-06 | Conopco, Inc., D/B/A Unilever | An effective anti-acne personal care composition |
CA3171721A1 (en) | 2020-03-19 | 2021-09-23 | Fritz Eichenseher | A stabilized protein of interest |
EP4289949A1 (en) | 2021-02-08 | 2023-12-13 | Wuhan Lysigen Bio-Tech Company Limited | Bacteriophage lysine, chimera thereof and application thereof |
WO2022225267A1 (ko) * | 2021-04-19 | 2022-10-27 | 엠브릭스 주식회사 | 보툴리늄 독소 전위 도메인 및 엔도라이신을 포함하는 단백질 복합체 및 이를 포함하는 항균 조성물 |
WO2023168418A1 (en) * | 2022-03-03 | 2023-09-07 | Massachusetts Institute Of Technology | Cell-wall binding protein specifically targeting cutibacterium acnes |
CN114540385B (zh) * | 2022-03-21 | 2023-06-23 | 齐鲁工业大学 | 一种利用大肠杆菌产溶葡萄球菌酶的方法 |
CN114349870B (zh) * | 2022-03-21 | 2022-06-03 | 天津辅元生物医药科技有限公司 | 一种兼具防粘连功效的重组抗菌肽及其制备方法和应用 |
Family Cites Families (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2132088A (en) | 1987-07-06 | 1989-01-30 | Louisiana State University Agricultural And Mechanical College | Inhibition of eucaryotic pathogens and neoplasms and stimulation of fibroblasts and lymphocytes with lytic peptides |
GB8816693D0 (en) | 1988-07-13 | 1988-08-17 | Agricultural & Food Res | Viral enzyme & gene |
GB2255561B (en) | 1991-04-20 | 1995-06-21 | Agricultural & Food Res | Lysins from bacteriophages |
DE69332740T2 (de) | 1992-08-21 | 2004-02-05 | The University Of British Columbia, Vancouver | Kationische peptide und verfahren zu deren herstellung |
PT778733E (pt) | 1994-09-01 | 2001-06-29 | Novozymes As | Composicao proteica basica para matar ou inibir celulas microbianas |
US6503881B2 (en) * | 1996-08-21 | 2003-01-07 | Micrologix Biotech Inc. | Compositions and methods for treating infections using cationic peptides alone or in combination with antibiotics |
US5997862A (en) | 1997-10-31 | 1999-12-07 | New Horizons Diagnostics Corporation | Therapeutic treatment of group A streptococcal infections |
US6428784B1 (en) | 1997-10-31 | 2002-08-06 | New Horizons Diagnostics Corp | Vaginal suppository for treating group B Streptococcus infection |
US20030113298A1 (en) | 1997-10-31 | 2003-06-19 | Vincent Fischetti | Use of bacterial phage associated lysing proteins for the prophylactic and therapeutic treatment of various illnesses |
US6288212B1 (en) | 1998-08-28 | 2001-09-11 | The University Of British Columbia | Anti-endotoxic, antimicrobial cationic peptides and methods of use therefor |
US5993809A (en) * | 1998-11-18 | 1999-11-30 | Children's Hospital Medical Center | Lysozyme fusion proteins in infections |
WO2001000855A1 (en) | 1999-06-23 | 2001-01-04 | Ppl Therapeutics (Scotland) Ltd. | Fusion proteins incorporating lysozyme |
US7338936B2 (en) | 2000-11-28 | 2008-03-04 | House Ear Institute | Use of antimicrobial proteins and peptides for the treatment of otitis media and paranasal sinusitis |
EP1501935B1 (en) | 2002-04-22 | 2009-09-23 | Dow Global Technologies Inc. | Low-cost production of peptides |
US7566447B2 (en) | 2003-05-15 | 2009-07-28 | Iogenetics, Llc | Biocides |
EP1680503B1 (en) | 2003-09-11 | 2011-06-22 | Novozymes Adenium Biotech A/S | Recombinant production of antimicrobial agents |
WO2005108563A2 (en) | 2004-04-19 | 2005-11-17 | University Of Chicago | Peptidoglycan-hydrolyzing protein encoded by bacteriophage n4 |
US7572602B1 (en) | 2004-12-03 | 2009-08-11 | The United States Of America As Represented By The Secretary Of Agriculture | Nucleic acid encoding endolysin fusion protein |
DE102005040347A1 (de) | 2005-08-25 | 2007-03-01 | Profos Ag | Verfahren und Mittel zur Anreicherung, Entfernung und zum Nachweis von Listerien |
ES2346808T3 (es) | 2006-03-31 | 2010-10-20 | The University Court Of The University Of St. Andrews | Composiciones antimicrobianas que comprenden un peptido cationico y una endopeptidasa de glicilglicina. |
DE102006061002A1 (de) | 2006-12-22 | 2008-06-26 | Profos Ag | Verfahren und Mittel zur Anreicherung, Entfernung und zum Nachweis von gram-positiven Bakterien |
US9296789B2 (en) * | 2007-09-25 | 2016-03-29 | Pastoral Greenhouse Gas Research Ltd. | Vaccines and vaccine components for inhibition of microbial cells |
US20100310522A1 (en) | 2007-11-26 | 2010-12-09 | Plant Bioscience Limited | Novel Polypeptides Having Endolysin Activity and Uses Thereof |
US8481289B2 (en) | 2008-07-24 | 2013-07-09 | The United States Of America, As Represented By The Secretary Of Agriculture | Triple acting antimicrobials that are refractory to resistance development |
EP2157100A1 (en) * | 2008-08-19 | 2010-02-24 | Profos AG | Artificial peptidoglycan lysing enzymes and peptidoglycan binding proteins |
GB0815484D0 (en) * | 2008-08-26 | 2008-10-01 | Univ Leuven Kath | Antibacterial agents |
US8389679B2 (en) * | 2009-02-05 | 2013-03-05 | The Regents Of The University Of California | Targeted antimicrobial moieties |
DE102010014867A1 (de) * | 2009-04-17 | 2010-11-18 | Sms Siemag Ag | Verfahren zum Bereitstellen mindestens einer Arbeitswalze zum Walzen eines Walzguts |
US8383102B2 (en) | 2009-05-21 | 2013-02-26 | The United States Of America As Represented By The Secretary Of Agriculture | Fusion of peptidoglycan hydrolase enzymes to a protein transduction domain allows eradication of both extracellular and intracellular gram positive pathogens |
KR101701890B1 (ko) | 2009-06-26 | 2017-02-02 | 뤼산도 아게 | 항균제 |
KR20170024129A (ko) | 2009-06-26 | 2017-03-06 | 카톨리에케 유니버시테이트 루벤 | 항균제 |
MX2012002216A (es) | 2009-08-24 | 2012-04-10 | Univ Leuven Kath | Nueva endolisina obpgplys. |
MX340520B (es) | 2010-04-27 | 2016-07-12 | Lysando Ag * | Metodo de reduccion de biopeliculas. |
US9388400B2 (en) * | 2012-06-29 | 2016-07-12 | Lysando Ag | Composition for use in mycobacteria diagnosis |
-
2010
- 2010-06-28 KR KR1020127002109A patent/KR101701890B1/ko active IP Right Grant
- 2010-06-28 MX MX2011013453A patent/MX2011013453A/es active IP Right Grant
- 2010-06-28 AU AU2010264659A patent/AU2010264659B2/en active Active
- 2010-06-28 WO PCT/EP2010/059152 patent/WO2010149795A1/en active Application Filing
- 2010-06-28 EP EP18165516.8A patent/EP3363896A1/en active Pending
- 2010-06-28 CA CA2765810A patent/CA2765810C/en active Active
- 2010-06-28 BR BRPI1015203-2A patent/BRPI1015203B1/pt active IP Right Grant
- 2010-06-28 JP JP2012516777A patent/JP6034188B2/ja active Active
- 2010-06-28 CN CN201080037886.7A patent/CN102482655B/zh active Active
- 2010-06-28 SG SG2012003745A patent/SG177704A1/en unknown
- 2010-06-28 US US13/380,329 patent/US20120195872A1/en not_active Abandoned
- 2010-06-28 EA EA201270082A patent/EA038542B1/ru unknown
- 2010-06-28 EP EP10727421.9A patent/EP2446028B1/en active Active
-
2011
- 2011-12-21 IL IL217121A patent/IL217121B/en active IP Right Grant
-
2016
- 2016-07-01 JP JP2016131194A patent/JP2017018092A/ja active Pending
-
2019
- 2019-01-29 US US16/260,407 patent/US11136570B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
EP2446028B1 (en) | 2018-04-04 |
CN102482655A (zh) | 2012-05-30 |
JP2012530510A (ja) | 2012-12-06 |
EP3363896A1 (en) | 2018-08-22 |
JP2017018092A (ja) | 2017-01-26 |
CA2765810A1 (en) | 2010-12-29 |
US20120195872A1 (en) | 2012-08-02 |
BRPI1015203A2 (pt) | 2016-08-02 |
EA201270082A1 (ru) | 2012-06-29 |
US20190218538A1 (en) | 2019-07-18 |
CA2765810C (en) | 2018-10-16 |
JP6034188B2 (ja) | 2016-11-30 |
IL217121A0 (en) | 2012-02-29 |
AU2010264659A1 (en) | 2011-12-15 |
KR20120061802A (ko) | 2012-06-13 |
WO2010149795A1 (en) | 2010-12-29 |
AU2010264659B2 (en) | 2016-08-04 |
IL217121B (en) | 2019-08-29 |
CN102482655B (zh) | 2018-04-10 |
EP2446028A1 (en) | 2012-05-02 |
EA038542B1 (ru) | 2021-09-13 |
US11136570B2 (en) | 2021-10-05 |
BRPI1015203B1 (pt) | 2021-06-01 |
KR101701890B1 (ko) | 2017-02-02 |
SG177704A1 (en) | 2012-02-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2011013453A (es) | Agentes antimicrobianos. | |
MX2011013288A (es) | Agentes antimicrobianos. | |
MX344257B (es) | Agentes antimicrobianos. | |
AU2010288559A8 (en) | New endolysin OBPgpLYS | |
GB201018518D0 (en) | Novel endolysin | |
WO2010023207A3 (en) | Antimicrobial agents | |
MX340520B (es) | Metodo de reduccion de biopeliculas. | |
Mercer et al. | Antimicrobial susceptibility testing of antimicrobial peptides to better predict efficacy | |
Sojka et al. | Antibiofilm efficacy of honey and bee-derived defensin-1 on multispecies wound biofilm | |
Menousek et al. | Database screening and in vivo efficacy of antimicrobial peptides against methicillin-resistant Staphylococcus aureus USA300 | |
JP2014500714A5 (es) | ||
JP2012530510A5 (es) | ||
EA201991233A1 (ru) | Новый эндолизин | |
WO2011110655A3 (en) | Immunogenic composition or vaccine against gram - negative bacterial, for example neiserial, infection or disease | |
KR102573154B1 (ko) | 변성 펩티드 | |
MX2019011808A (es) | Endolisinas de gram-negativas modificadas. | |
EP3313862B9 (en) | Broad-spectrum anti-infective peptides | |
Ho et al. | Bacteriophage endolysins against gram-positive bacteria, an overview on the clinical development and recent advances on the delivery and formulation strategies | |
Da Silva et al. | Antibacterial activity of a novel antimicrobial peptide [W7] KR12-KAEK derived from KR-12 against Streptococcus mutans planktonic cells and biofilms | |
BR112014027629A2 (pt) | misturas de polipeptídeo com atividade antibacteriana | |
Heinzinger et al. | Evaluating the Translational Potential of Bacteriocins as an Alternative Treatment for Staphylococcus aureus Infections in Animals and Humans | |
PL243303B1 (pl) | Rekombinowany polipeptyd do zastosowania do leczenia, kompozycje go zawierające oraz jego zastosowania | |
Lewies | An in vitro evaluation of the antibacterial and anticancer properties of the antimicrobial peptide nisin Z | |
TH120357B (th) | สารต้านจุลินทรีย์ | |
TH120358B (th) | สารต้านจุลินทรีย์ |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
HC | Change of company name or juridical status |
Owner name: ELANCO ANIMAL HEALTH IRELAND LIMITED |
|
FG | Grant or registration |